Drug Launches: Is It Better To Be The Tortoise Or The Hare?
Executive Summary
As companies present their third quarter earnings they discuss the drugs that they’ve launched over the last quarter – some have had success right out of the gate, while others hope to build momentum, albeit more slowly.
You may also be interested in...
Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.
Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa
Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.